Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.

Leukemia · 2021 · PMC8632691 · PMID 34023851

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In general the hazard ratio in RUX pretreated patients for NRM, relapse, EFS, and OS was always <1.0 ranging from 0.68 to 0.81, but did not reach statistical significance for these outcome variables.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.